S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

INCY Incyte Corporation

53.14

0.05 (0.09%)

Last Updated: 02:47:42

Delayed by 15 minutes

Incyte withdraws NDA for lymphoma treatment parsaclisib

To read the full story on Seeking Alpha, click here.

Incyte (NASDAQ:INCY)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Incyte Charts.

Incyte (NASDAQ:INCY)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Incyte Charts.

Incyte Corporation News

Incyte to Present at Upcoming Investor Conference
Thursday 2 May 2024 (1 day ago) • Business Wire

Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
Tuesday 30 April 2024 (3 days ago) • Business Wire

Incyte annonce l'acquisition d'Escient Pharmaceuticals et de son portefeuille d'antagonistes MRGPR oraux premiers de leur catégorie
Wednesday 24 April 2024 (1 week ago) • Business Wire

Incyte gibt Übernahme von Escient Pharmaceuticals und dessen Pipeline oraler First-in-Class-MRGPR-Antagonisten bekannt
Wednesday 24 April 2024 (1 week ago) • Business Wire

Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
Tuesday 23 April 2024 (1 week ago) • Business Wire

Incyte to Report First Quarter Financial Results
Thursday 11 April 2024 (3 weeks ago) • Business Wire

Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
Monday 1 April 2024 (1 month ago) • Business Wire

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Saturday 30 March 2024 (1 month ago) • Business Wire

Incyte annonce de nouvelles données de l’étude de phase 2 évaluant le ruxolitinib crème (Opzelura®) chez les patients atteints d’hidradénite suppurée légère à modérée
Monday 11 March 2024 (2 months ago) • Business Wire

Incyte présente de nouvelles données de l’étude de phase 2 évaluant le povorcitinib chez des patients atteints de prurigo nodulaire
Monday 11 March 2024 (2 months ago) • Business Wire

Incyte legt neue brandaktuelle Daten aus Phase-2-Studie zur Prüfung von Povorcitinib bei Patienten mit Prurigo nodularis vor
Monday 11 March 2024 (2 months ago) • Business Wire

Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
Monday 11 March 2024 (2 months ago) • Business Wire

More Incyte Corporation News Articles

Woodside Petroleum

AUD vs US Dollar

Commonwealth Bank Of Aus...

Invesco QQQ Trust Series 1

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions